|
Cost-effectiveness of the addition of rituximab to CHOP chemotherapy in first-line treatment for diffuse large B-cell lymphoma in a population-based observational cohort in British Columbia, Canada |
Johnston KM, Marra CA, Connors JM, Najafzadeh M, Sehn L, Peacock SJ |
|
|
Record Status This is an economic evaluation that meets the criteria for inclusion on NHS EED. Bibliographic details Johnston KM, Marra CA, Connors JM, Najafzadeh M, Sehn L, Peacock SJ. Cost-effectiveness of the addition of rituximab to CHOP chemotherapy in first-line treatment for diffuse large B-cell lymphoma in a population-based observational cohort in British Columbia, Canada. Value in Health 2010; 13(6): 703-711 Indexing Status Subject indexing assigned by NLM MeSH Antibodies, Monoclonal, Murine-Derived /administration & Antineoplastic Combined Chemotherapy Protocols /administration & British Columbia; Cohort Studies; Computer Simulation; Cost-Benefit Analysis; Cyclophosphamide /administration & Doxorubicin /administration & Humans; Lymphoma, Large B-Cell, Diffuse /drug therapy /economics; Middle Aged; Outcome and Process Assessment (Health Care); Prednisone /administration & Quality-Adjusted Life Years; Rituximab; Survival Analysis; Vincristine /administration & dosage /economics; dosage /economics; dosage /economics; dosage /economics; dosage /economics; dosage /economics AccessionNumber 22010001706 Date bibliographic record published 05/01/2011 |
|
|
|